Studies from Pevion Biotech Ltd. update current data on biotechnology business
2007 NOV 19 -- Fresh data on biotechnology business are presented in the report 'A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses.' "The purpose of a vaccine is the induction of effective cellular and/or humoral immune responses against antigens. Because defined antigens are often poor immunogens when administered alone, an adjuvant is required to potentiate the immune response," researchers in Bern, Switzerland report. "Most of these adjuvants are designed to induce humoral immune responses, including immunopotentiating reconstituted influenza virosomes (IRIVs). IRIVs are one of the few adjuvants currently licensed for human use with the advantage of an excellent safety profile. To induce a potent cytotoxic T lymphocyte (CTL) immune response CTL epitopes have to be encapsulated into IRIVs. However, the existing encapsulation methods are inefficient or rather laborious. We have developed and characterised a new generation of influenza virosomes (TIRIVs) that induced both, strong CTL and antibody responses against specific antigens of choice. In addition, these virosomes were stabilised and offer the possibility of lyophilisation while retaining all their structural, functional and immunogenic properties after reconstitution. TIRIVs induce strong cellular and humoral immune responses and are a versatile and efficient carrier system with adjuvant properties for a variety of antigens. TIRIVs are not only stabilised but also allow easy formulation of new and/or labile T cell and B cell antigens," wrote A.R. Kammer and colleagues, Pevion Biotech Ltd.. The researchers concluded: "Considering their immunogenic properties, their flexibility and their superior storage characteristics TIRIVs provide a versatile technology platform for any vaccination strategy." Kammer and colleagues published their study in Vaccine (A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine, 2007;25(41):7065-74). For additional information, contact A.R. Kammer, Pevion Biotechnology Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland. Publisher contact information for the journal Vaccine is: Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. Keywords: Switzerland, Bern, Biotechnology, Biotechnology Business, Biotechnology Company, Pevion Biotech Ltd., Vaccines. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
